[Hyperacute graft versus host disease after allo-stem cell transplantation, analysis of 118 cases].
OBJECTIVE
To investigate the clinical manifestations, management, prognosis, and risk factors of hyperacute graft versus host disease (hGVHD) after allo-SCT cell transplantation all-SCT.


METHODS
The data of 118 patients aged 2 approximately 52 who underwent 120 times of allo-SCT were analyzed retrospectively.


RESULTS
hGVHD was observed in 17 patients with an incidence rate of 14.17%. The clinical manifestations included gastrointestinal symptoms (13/17), rash (13/17), fever (8/17), and hepatic dysfunction (6/17). Another 12 cases with only one organ injured were included in atypical hGVHD group. The two-year survival rates were 30.50%, 40.00%, and 61.67% in patients with typical hGVHD, patients with atypical hGVHD, and patients without hGVHD respectively. The condition of twenty-five cases with hGVHD improved after treatment with immunosuppressive drugs.


CONCLUSIONS
hGVHD is a common complication after allo-SCT that affects the prognosis dramatically. The risk factors of hGVHD include HLA mismatching, disease being in progressive stage just before allo-SCT, female in sex, and sex mismatching.
Huang
Xiaojun
X
Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China.
Chen
Yuhong
Y
Guo
Nailan
N
Ren
Hanyun
H
Zhang
Yaochen
Y
Xu
Lanping
L
Gao
Zhiyong
Z
Lu
Daopei
D
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000503:physiopathology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D008727:Methotrexate